ORIENT BIO Inc.

A002630

KR7002630002

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
522 ^KRW	-0.76%		-1.51%	-14.00%

2022	Pregen Inc. announced that it has received KRW 1.7 billion in funding from Orient Co.,Ltd, ORIENT BIO Inc., ORIENT WATCH CO.,LTD.	CI
2022	Pregen Inc. announced that it expects to receive KRW 1.7 billion in funding from Orient Co.,Ltd, ORIENT BIO Inc., ORIENT WATCH CO.,LTD. and other investors	CI

ORIENT BIO Inc. announced that it has received KRW 11.67259512 billion in funding from MDAS Inc., Orient Precision Industries Inc.

August 04, 2020

On August 5, 2020, ORIENT BIO Inc. (KOSE:A002630) closed the transaction.

Latest news about ORIENT BIO Inc.

Pregen Inc. announced that it has received KRW 1.7 billion in funding from Orient Co.,Ltd, ORIENT BIO Inc., ORIENT WATCH CO.,LTD.	22-12-15	CI
Pregen Inc. announced that it expects to receive KRW 1.7 billion in funding from Orient Co.,Ltd, ORIENT BIO Inc., ORIENT WATCH CO.,LTD. and other investors	22-11-30	CI
Orient Electronics Co.,Ltd. announced that it has received KRW 3.049998525 billion in funding from Orient Precision Industries Inc, ORIENT BIO Inc.	22-08-09	CI
Orient Electronics Co.,Ltd. announced that it expects to receive KRW 3.049998525 billion in funding from Orient Precision Industries Inc, ORIENT BIO Inc.	22-07-19	CI
ORIENT BIO Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-14	CI
Inotiv, Inc. acquired Orient BioResource Center, Inc. from ORIENT BIO Inc. for $51.3 million.	22-01-26	CI
ORIENT BIO Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-14	CI
ORIENT BIO Inc.(KOSE:A002630) dropped from S&P Global BMI Index	20-09-21	CI
ORIENT BIO Inc. announced that it has received KRW 11.67259512 billion in funding from MDAS Inc., Orient Precision Industries Inc.	20-08-04	CI
ORIENT BIO Inc. announced that it expects to receive KRW 11.67259512 billion in funding from MDAS Inc., Orient Precision Industries Inc.	20-07-27	CI
ORIENT BIO Inc. agreed to acquire an additional 29.74% stake in Orient Electronics Co.,Ltd. for KRW 6.7 billion.	20-07-27	CI
ORIENT BIO Inc. announced that it has received KRW 4.64699064 billion in funding	19-12-23	CI
Orient Precision Industries Inc. cancelled the acquisition of an additional 27.6% stake in Orient Electronics Co.,Ltd from ORIENT BIO Inc..	18-03-27	CI
ORIENT BIO Inc. announced that it has received KRW 30 billion in funding	17-05-15	CI
Orient Bio, Inc. to Raise USD 26.4 Million in Private Placement of Bonds Due 2021	17-04-16	CI
ORIENT BIO Inc. announced that it expects to receive KRW 30 billion in funding	17-04-13	CI
Orient Precision Industries Inc. announced that it has received KRW 5 billion in funding from ORIENT BIO Inc., Mdas Inc.	17-04-04	CI
Orient Precision Industries Inc. announced that it expects to receive KRW 5 billion in funding from ORIENT BIO Inc., Mdas Inc.	17-04-03	CI
Orient Precision Industries Inc. agreed to acquire an additional 27.6% stake in Orient Electronics Co.,Ltd from ORIENT BIO Inc. for KRW 5 billion.	17-03-27	CI
ORIENT BIO Inc. announced that it has received KRW 10 billion in funding from Eugene investment & Securities Co., Ltd., Investment Arm	16-06-02	CI
ORIENT BIO Inc. announced that it expects to receive KRW 10 billion in funding from Eugene investment & Securities Co., Ltd., Investment Arm	16-05-31	CI
ORIENT BIO Inc. announced that it has received KRW 7 billion in funding from Eugene investment & Securities Co., Ltd., Investment Arm	15-10-15	CI
ORIENT BIO Inc. announced that it expects to receive KRW 7 billion in funding from Eugene investment & Securities Co., Ltd., Investment Arm	15-10-13	CI
ORIENT BIO Inc.(KOSE:A002630) added to S&P Global BMI Index	15-09-21	CI
Orientbio, Inc. cancelled the acquisition of an additional 7.19% stake in Orient Precision Industries Inc.	12-11-20	CI

ORIENT BIO Inc. is a Korea-based company engaged in the biotechnology area. The Company produces and supplies laboratory animals, including mice, rats, guinea pigs, hamsters, specific pathogen free (SPF) rabbits, beagles and others. It also provides contract research organization (CRO) services, including CRO safety assessment and CRO new drug development services; medical and library equipment, such as barrier systems, and support services such as rodent surgery services, laboratory diagnostics services, transgenic services, genetic testing services and other services. In addition, along with its subsidiaries, the Company provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines.

Sector

Biotechnology & Medical Research

Calendar

2024-08-13 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ORIENT BIO INC.	-14.00%	44.73M
VERTEX PHARMACEUTICALS INCORPORATED	-1.65%	104B
REGENERON PHARMACEUTICALS, INC.	+6.75%	97.47B
ARGENX SE	+5.71%	22.25B
BIONTECH SE	-12.60%	21.68B
GENMAB A/S	-9.70%	18.2B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-10.17%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+6.12%	14.39B
SAREPTA THERAPEUTICS, INC.	+35.47%	12.37B

Bio Therapeutic Drugs

ORIENT BIO Inc.

Equities

A002630

KR7002630002

Biotechnology & Medical Research

ORIENT BIO Inc. announced that it has received KRW 11.67259512 billion in funding from MDAS Inc., Orient Precision Industries Inc.

Latest news about ORIENT BIO Inc.

Chart ORIENT BIO Inc.

Company Profile

Sector Bio Therapeutic Drugs